iSpecimen Inc. ISPC
mission is to accelerate life science research, discovery and development with a global marketplace platform that connects researchers
to subjects, specimens, and associated data. Our vision is to create an "Amazon-like" global Marketplace of patients, biospecimens,
and data for research to improve the quality of human life. We implement employee programs that foster a company culture predicated on
the core values of corporate and individual growth, results and accountability, team before self; a can-do positive attitude, and the
Last close
0.82
2026-10-23
Market cap
$2.1M
2026-06-30 share count
52-week range
0.79 - 34.80
Valuation FY2025 figures against the last close
P/S1.1x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-2.28
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.9M | $9.3M | $9.9M | $10.4M | $11.1M | $8.2M | — |
| Cost of revenue | $1.7M | $5.1M | $4.8M | $4.8M | $5.2M | $3.6M | — |
| Gross profit | $215.7K | $4.2M | $5.2M | $5.6M | $5.9M | $4.6M | — |
| R&D | — | $1.5M | $1.6M | $1.5M | $879.2K | $319.2K | — |
| SG&A | $3.5M | $6.1M | $5.9M | $6.9M | $5.6M | $2.4M | — |
| Total operating expenses | $10.9M | $22.0M | $21.1M | $20.6M | $17.1M | $10.6M | — |
| Operating income | -$9.0M | -$12.7M | -$11.2M | -$10.2M | -$5.9M | -$2.4M | — |
| Interest expense | $1.9K | $173.8K | $16.0K | $239.0K | $2.1M | $2.1M | — |
| Pre-tax income | — | — | — | -$10.2M | -$9.0M | -$4.7M | — |
| Income tax | — | — | — | $0 | $0 | $0 | — |
| Net income | -$10.5M | -$12.5M | -$11.1M | -$10.2M | -$9.0M | -$4.7M | — |
| EPS, basic | -2.28 | -17.58 | -24.55 | -1.16 | -2.09 | -4.97 | — |
| EPS, diluted | -2.28 | -17.58 | -24.55 | -1.16 | -2.09 | -4.97 | — |
| Shares, diluted (wtd. avg.) | 4.6M | 710,852 | 452,067 | 8.8M | 4.3M | 936,213 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $6.9M | $1.9M | $2.3M | $15.3M | $27.7M | $695.9K | $53.9K |
| Short-term investments | — | — | $2.7M | $0 | — | — | — |
| Receivables | $48.3K | $1.4M | $728.4K | $1.6M | $3.0M | $1.5M | — |
| Inventory | — | $45.1K | — | — | — | — | — |
| Total current assets | $7.0M | $3.6M | $8.2M | $19.7M | $32.9M | $3.5M | — |
| Property, plant and equipment | $25.5K | $93.6K | $127.8K | $225.9K | $32.8K | $75.6K | — |
| Total assets | $9.5M | $9.4M | $15.8M | $24.6M | $35.7M | $6.2M | — |
| Accounts payable | $5.4M | $4.2M | $3.9M | $2.5M | $832.7K | $1.8M | — |
| Short-term debt | — | $1.0M | — | — | — | — | — |
| Total current liabilities | $6.2M | $5.8M | $6.0M | $4.3M | $2.5M | $22.1M | — |
| Long-term debt | — | — | — | — | $3.4M | — | — |
| Total liabilities | $6.4M | $6.0M | $6.1M | $4.3M | $5.9M | $22.3M | — |
| Retained earnings | -$82.4M | -$71.9M | -$59.4M | -$48.3M | -$38.0M | -$29.1M | — |
| Total equity | $3.1M | $3.3M | $9.7M | $20.3M | $29.8M | -$27.3M | -$22.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.2M | -$8.3M | -$5.8M | -$5.8M | -$10.7M | -$288.4K | — |
| Depreciation and amortisation | $68.5K | $65.7K | $117.5K | $22.4K | $45.4K | $44.8K | — |
| Stock-based compensation | $21.3K | $249.7K | $459.7K | $678.6K | $622.1K | $92.9K | — |
| Capital expenditure | $454 | $31.5K | $19.5K | $215.5K | $2.5K | $426 | — |
| Investing cash flow | -$1.0M | $2.0M | -$7.2M | -$3.2M | -$1.0M | -$1.1M | — |
| Financing cash flow | $10.2M | $5.8M | $70.9K | -$3.4M | $38.7M | $2.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-038607.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $8.2M | $11.1M | $10.4M | $9.9M | $9.3M | $1.9M |
| Gross profit | — | $4.6M | $5.9M | $5.6M | $5.2M | $4.2M | $215.7K |
| Net income | — | -$4.7M | -$9.0M | -$10.2M | -$11.1M | -$12.5M | -$10.5M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Material agreement signed Item 1.01
- Material agreement signed Item 1.01
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Material agreement signed Item 1.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed Item 1.01
- Delisting notice Item 3.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8731
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IQV | IQVIA HOLDINGS INC. | $46.63B | 35.6x | 5.9% |
| INCY | INCYTE CORP | $23.12B | 18.1x | 21.2% |
| MEDP | Medpace Holdings, Inc. | $18.68B | 43.8x | 20.0% |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $16.49B | — | -0.9% |
| ABSI | Absci Corp | $1.58B | — | -38.2% |
| OABI | OmniAb, Inc. | $677.5M | — | -29.3% |
| NRC | NRC HEALTH | $485.1M | 0.4x | -4.0% |
| ONMD | OneMedNet Corp | $279.2M | — | 111.4% |